JP2024512154A5 - - Google Patents
Info
- Publication number
- JP2024512154A5 JP2024512154A5 JP2023560811A JP2023560811A JP2024512154A5 JP 2024512154 A5 JP2024512154 A5 JP 2024512154A5 JP 2023560811 A JP2023560811 A JP 2023560811A JP 2023560811 A JP2023560811 A JP 2023560811A JP 2024512154 A5 JP2024512154 A5 JP 2024512154A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- stereoisomer
- solvate
- oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168407P | 2021-03-31 | 2021-03-31 | |
| US63/168,407 | 2021-03-31 | ||
| US202263318118P | 2022-03-09 | 2022-03-09 | |
| US63/318,118 | 2022-03-09 | ||
| PCT/US2022/022525 WO2022212489A1 (en) | 2021-03-31 | 2022-03-30 | Mk2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024512154A JP2024512154A (ja) | 2024-03-18 |
| JP2024512154A5 true JP2024512154A5 (enExample) | 2026-04-03 |
| JP7887433B2 JP7887433B2 (ja) | 2026-07-09 |
Family
ID=83459911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560811A Active JP7887433B2 (ja) | 2021-03-31 | 2022-03-30 | Ｍｋ２阻害剤及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11680056B2 (enExample) |
| EP (1) | EP4313970A4 (enExample) |
| JP (1) | JP7887433B2 (enExample) |
| KR (1) | KR20230163501A (enExample) |
| AU (1) | AU2022252242A1 (enExample) |
| BR (1) | BR112023019861A2 (enExample) |
| CA (1) | CA3215746A1 (enExample) |
| CL (1) | CL2023002921A1 (enExample) |
| CO (1) | CO2023013150A2 (enExample) |
| CR (1) | CR20230468A (enExample) |
| DO (1) | DOP2023000212A (enExample) |
| IL (1) | IL307187A (enExample) |
| MX (1) | MX2023011503A (enExample) |
| PE (1) | PE20240144A1 (enExample) |
| TW (1) | TW202304879A (enExample) |
| WO (1) | WO2022212489A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116425722B (zh) * | 2022-01-13 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮-芳(杂)环类化合物及其制备方法与应用 |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| CN117800948A (zh) * | 2022-05-12 | 2024-04-02 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
| TW202412792A (zh) * | 2022-08-30 | 2024-04-01 | 大陸商長春金賽藥業有限責任公司 | ｐ３８α－ＭＫ２抑制劑化合物、藥物組合物及其用途 |
| US20240182449A1 (en) * | 2022-10-05 | 2024-06-06 | Xinthera, Inc. | Crystalline forms of an mk2 inhibitor |
| CN118047757A (zh) * | 2022-11-16 | 2024-05-17 | 上海美悦生物科技发展有限公司 | 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途 |
| US20260217652A1 (en) * | 2023-01-13 | 2026-07-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| CN121368484A (zh) * | 2023-06-26 | 2026-01-20 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| EP1987022A1 (en) * | 2006-02-10 | 2008-11-05 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| JP2010529129A (ja) * | 2007-06-06 | 2010-08-26 | タイロジェネックス，インコーポレイテッド | キナーゼ阻害剤化合物 |
| EP2437598A4 (en) | 2009-06-03 | 2012-10-31 | Glaxosmithkline Llc | BIS-PYRIDYLPYRIDONES AS MELANGE-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS |
| DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| JP2014531425A (ja) | 2011-09-02 | 2014-11-27 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤 |
| US9056110B2 (en) * | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| US9365540B2 (en) * | 2012-01-12 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as MCH receptor antagonists |
| KR102313515B1 (ko) * | 2013-06-07 | 2021-10-14 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물 |
| CN114206339A (zh) | 2019-07-31 | 2022-03-18 | 阿克拉瑞斯治疗股份有限公司 | 氘化mk2途径抑制剂及其使用方法 |
| IL296054A (en) | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| KR20230112696A (ko) | 2020-11-23 | 2023-07-27 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 합성 방법 |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| PY2222114A (es) | 2021-03-31 | 2023-01-19 | Syngenta Crop Protection Ag | Derivados microbiocidas de quinolin/quinoxalin-benzotiazina |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| US11780832B2 (en) | 2021-03-31 | 2023-10-10 | Fedora Pharmaceuticals Inc. | Lactivicin compounds, their preparation and use as antibacterial agents |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| US20230135894A1 (en) | 2021-06-30 | 2023-05-04 | Kymera Therapeutics, Inc. | Mk2 degraders and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| WO2023001282A1 (zh) | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TW202315625A (zh) | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途 |
| CN116178345B (zh) | 2021-10-19 | 2024-08-13 | 深圳信立泰药业股份有限公司 | 一种取代的嘧啶基-吡啶基-吡啶酮化合物及其制备方法与应用 |
| WO2023125708A1 (zh) | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116444492B (zh) | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN115636814A (zh) | 2022-02-28 | 2023-01-24 | 瑞石生物医药有限公司 | 一种嘧啶衍生物及其用途 |
-
2022
- 2022-03-30 WO PCT/US2022/022525 patent/WO2022212489A1/en not_active Ceased
- 2022-03-30 BR BR112023019861A patent/BR112023019861A2/pt not_active Application Discontinuation
- 2022-03-30 CR CR20230468A patent/CR20230468A/es unknown
- 2022-03-30 JP JP2023560811A patent/JP7887433B2/ja active Active
- 2022-03-30 PE PE2023002765A patent/PE20240144A1/es unknown
- 2022-03-30 TW TW111112312A patent/TW202304879A/zh unknown
- 2022-03-30 MX MX2023011503A patent/MX2023011503A/es unknown
- 2022-03-30 EP EP22782084.2A patent/EP4313970A4/en active Pending
- 2022-03-30 AU AU2022252242A patent/AU2022252242A1/en active Pending
- 2022-03-30 KR KR1020237037138A patent/KR20230163501A/ko active Pending
- 2022-03-30 CA CA3215746A patent/CA3215746A1/en active Pending
- 2022-03-30 IL IL307187A patent/IL307187A/en unknown
- 2022-07-19 US US17/868,567 patent/US11680056B2/en active Active
-
2023
- 2023-05-02 US US18/310,943 patent/US12545662B2/en active Active
- 2023-07-13 US US18/352,078 patent/US11987574B2/en active Active
- 2023-09-29 DO DO2023000212A patent/DOP2023000212A/es unknown
- 2023-09-29 CL CL2023002921A patent/CL2023002921A1/es unknown
- 2023-10-02 CO CONC2023/0013150A patent/CO2023013150A2/es unknown